Similarly, IHC (Immunohistochemistry) quantified PD-L1 (CD274) expression, microsatellite instability, and Tumor Mutation Burden (TMB) have been used in clinical settings to assess whether NSCLC patients could benefit from Immune Checkpoint Inhibitor (ICIs) (Table S1A). The gene discussed is CD274; the disease is non-small cell lung carcinoma.